Prednisone-dependent asthma: inflammatory indices in induced sputum

The kinetics of changes in inflammatory indices in induced sputum from eight prednisone dependent asthmatics whose minimum clinical maintenance and exacerbation doses were known were investigated. The study began on the last day of a course of 30 mg prednisone daily for one week. Thereafter, the daily prednisone was reduced in a structured way to below the maintenance dose. This treatment was continued until a clinical exacerbation occurred. Prednisone 30 mg daily was then given again for one week. The mean duration of prednisone reduction was 7.4 weeks and the median dose was 7.5 mg x day(-1). Increases in sputum eosinophils preceded increases in blood eosinophils by 4 weeks and worsening of symptoms and forced expiratory volume in one second by 6 weeks. The clinical exacerbation was also accompanied by sputum neutrophilia and increases in sputum eosinophil cationic protein (ECP), fibrinogen and interleukin (IL)-5. Treatment with prednisone suppressed median sputum eosinophilia (from 16.3 to 0%, p<0.001), decreased sputum ECP (from 7,480 to 700 microg x L(-1), p = 0.01), but did not improve neutrophil numbers, fibrinogen or IL-5. The results show that the reduction of prednisone treatment in prednisone-dependent asthmatics evokes a severe airway eosinophilic inflammatory response. Clinical and blood indices deteriorate later than those in sputum suggesting that sputum examination may be useful to identify the minimum regular dose of prednisone required in these patients.

This article has been cited by other articles:

				H. K. Reddel, D. R. Taylor, E. D. Bateman, L.-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice Am. J. Respir. Crit. Care Med., July 1, 2009; 180(1): 59 - 99. [Abstract] [Full Text] [PDF]

				M. Malerba, B. Ragnoli, A. Radaeli, and C. Tantucci Usefulness of Exhaled Nitric Oxide and Sputum Eosinophils in the Long-term Control of Eosinophilic Asthma Chest, October 1, 2008; 134(4): 733 - 739. [Abstract] [Full Text] [PDF]

				E Sapey, D Bayley, A Ahmad, P Newbold, N Snell, and R A Stockley Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability Thorax, June 1, 2008; 63(6): 493 - 499. [Abstract] [Full Text] [PDF]

				K. Maneechotesuwan, S. Essilfie-Quaye, S. A. Kharitonov, I. M. Adcock, and P. J. Barnes Loss of Control of Asthma Following Inhaled Corticosteroid Withdrawal Is Associated With Increased Sputum Interleukin-8 and Neutrophils Chest, July 1, 2007; 132(1): 98 - 105. [Abstract] [Full Text] [PDF]

				L. Jayaram, M. M. Pizzichini, R. J. Cook, L-P. Boulet, C. Lemiere, E. Pizzichini, A. Cartier, P. Hussack, C. H. Goldsmith, M. Laviolette, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J., March 1, 2006; 27(3): 483 - 494. [Abstract] [Full Text] [PDF]

				L. Jayaram, M. Duong, M. M. M. Pizzichini, E. Pizzichini, D. Kamada, A. Efthimiadis, and F. E. Hargreave Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Eur. Respir. J., January 1, 2005; 25(1): 41 - 46. [Abstract] [Full Text] [PDF]

				A. Linden, M. Laan, and G. P. Anderson Neutrophils, interleukin-17A and lung disease Eur. Respir. J., January 1, 2005; 25(1): 159 - 172. [Abstract] [Full Text] [PDF]

				R. Gagliardo, P. Chanez, M. Mathieu, A. Bruno, G. Costanzo, C. Gougat, I. Vachier, J. Bousquet, G. Bonsignore, and A. M. Vignola Persistent Activation of Nuclear Factor-{kappa}B Signaling Pathway in Severe Uncontrolled Asthma Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1190 - 1198. [Abstract] [Full Text] [PDF]

				C E Brightling, F A Symon, S S Birring, P Bradding, A J Wardlaw, and I D Pavord Comparison of airway immunopathology of eosinophilic bronchitis and asthma Thorax, June 1, 2003; 58(6): 528 - 532. [Abstract] [Full Text] [PDF]

				R H Green, C E Brightling, I D Pavord, and A J Wardlaw Management of asthma in adults: current therapy and future directions Postgrad. Med. J., May 1, 2003; 79(931): 259 - 267. [Abstract] [Full Text] [PDF]

				M. Romagnoli, I. Vachier, P. Tarodo de la Fuente, H. Meziane, C. Chavis, J. Bousquet, P. Godard, and P. Chanez Eosinophilic inflammation in sputum of poorly controlled asthmatics Eur. Respir. J., December 1, 2002; 20(6): 1370 - 1377. [Abstract] [Full Text] [PDF]

				F. Kanniess, K. Richter, S. Janicki, M.B. Schleiss, R.A. Jorres, and H. Magnussen Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Eur. Respir. J., November 1, 2002; 20(5): 1080 - 1087. [Abstract] [Full Text] [PDF]

				F. Kanniess, K. Richter, S. Bohme, R.A. Jorres, and H. Magnussen Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Eur. Respir. J., October 1, 2002; 20(4): 853 - 858. [Abstract] [Full Text] [PDF]

				Leader of the Working Group: E. Pizzichini, Members of the Working Group:, M.M.M. Pizzichini, R. Leigh, R. Djukanovic, and P.J. Sterk Safety of sputum induction Eur. Respir. J., July 1, 2002; 20(37_suppl): 9S - 18s. [Full Text] [PDF]

				Leader of the Working Group: M.M. Kelly, Members of the Working Group:, V. Keatings, R. Leigh, C. Peterson, J. Shute, P. Venge, and R. Djukanovic Analysis of fluid{-}phase mediators Eur. Respir. J., July 1, 2002; 20(37_suppl): 24S - 39s. [Full Text] [PDF]

				C. Bonnans, I. Vachier, C. Chavis, P. Godard, J. Bousquet, and P. Chanez Lipoxins Are Potential Endogenous Antiinflammatory Mediators in Asthma Am. J. Respir. Crit. Care Med., June 1, 2002; 165(11): 1531 - 1535. [Abstract] [Full Text] [PDF]

				A B Chang, V A Harrhy, J Simpson, I B Masters, and P G Gibson Cough, airway inflammation, and mild asthma exacerbation Arch. Dis. Child., April 1, 2002; 86(4): 270 - 275. [Abstract] [Full Text] [PDF]

				D. Cataldo, J.-M. Foidart, L. Lau, P. Bartsch, R. Djukanovic, and R. Louis Induced Sputum : Comparison Between Isotonic and Hypertonic Saline Solution Inhalation in Patients With Asthma Chest, December 1, 2001; 120(6): 1815 - 1821. [Abstract] [Full Text] [PDF]

				S. L. JONES, J. KITTELSON, J. O. COWAN, E. M. FLANNERY, R. J. HANCOX, C. R. MCLACHLAN, and D. R. TAYLOR The Predictive Value of Exhaled Nitric Oxide Measurements in Assessing Changes in Asthma Control Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 738 - 743. [Abstract] [Full Text] [PDF]

				S. S. Salvi, M. T. Krishna, A. P. Sampson, and S. T. Holgate The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma Chest, May 1, 2001; 119(5): 1533 - 1546. [Abstract] [Full Text] [PDF]

				J. V. FAHY, H. A. BOUSHEY, S. C. LAZARUS, E. A. MAUGER, R. M. CHERNIACK, V. M. CHINCHILLI, T. J. CRAIG, J. M. DRAZEN, J. G. FORD, J. E. FISH, et al. Safety and Reproducibility of Sputum Induction in Asthmatic Subjects in a Multicenter Study Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1470 - 1475. [Abstract] [Full Text]

				N. E. Alexis, J. Soukup, S. Nierkens, and S. Becker Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma Am J Physiol Lung Cell Mol Physiol, February 1, 2001; 280(2): L369 - L375. [Abstract] [Full Text] [PDF]

				R. GAGLIARDO, P. CHANEZ, A. M. VIGNOLA, J. BOUSQUET, I. VACHIER, P. GODARD, G. BONSIGNORE, P. DEMOLY, and M. MATHIEU Glucocorticoid Receptor alpha and beta in Glucocorticoid Dependent Asthma Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 7 - 13. [Abstract] [Full Text]

				F. E. HARGREAVE and R. LEIGH Induced Sputum, Eosinophilic Bronchitis, and Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): S53 - 57. [Abstract] [Full Text] [PDF]